Checkpoint Therapeutics Inc
NASDAQ:CKPT

Watchlist Manager
Checkpoint Therapeutics Inc Logo
Checkpoint Therapeutics Inc
NASDAQ:CKPT
Watchlist
Price: 4.26 USD 0.71% Market Closed
Market Cap: $370.7m

Net Margin

-137 170.7%
Current
Declining
by 76 343.5%
vs 3-y average of -60 827.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-137 170.7%
=
Net Income
$-56.2m
/
Revenue
$41k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-137 170.7%
=
Net Income
$-56.2m
/
Revenue
$41k

Peer Comparison

Country Company Market Cap Net
Margin
US
Checkpoint Therapeutics Inc
NASDAQ:CKPT
356.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 15 072 companies
1st percentile
-137 170.7%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Checkpoint Therapeutics Inc
Glance View

Market Cap
370.7m USD
Industry
Biotechnology

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in New York City, New York and currently employs 14 full-time employees. The company went IPO on 2016-11-02. The firm is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, which is an epidermal growth factor receptor (EGFR) inhibitor as a treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

CKPT Intrinsic Value
24.38 USD
Undervaluation 83%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-137 170.7%
=
Net Income
$-56.2m
/
Revenue
$41k
What is Checkpoint Therapeutics Inc's current Net Margin?

The current Net Margin for Checkpoint Therapeutics Inc is -137 170.7%, which is below its 3-year median of -60 827.3%.

How has Net Margin changed over time?

Over the last 3 years, Checkpoint Therapeutics Inc’s Net Margin has decreased from -20 988.9% to -137 170.7%. During this period, it reached a low of -137 170.7% on Jan 31, 2025 and a high of -20 988.9% on Dec 1, 2021.

Back to Top